ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ABCL AbCellera Biologics Inc

3.8203
-0.1297 (-3.28%)
11 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
AbCellera Biologics Inc NASDAQ:ABCL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.1297 -3.28% 3.8203 3.64 19.00 3.97 3.81 3.92 1,193,867 05:00:00

AbCellera to Present at Upcoming Investor Conferences in March

23/02/2024 1:15am

Business Wire


AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart


From Feb 2024 to May 2024

Click Here for more AbCellera Biologics Charts.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:

  • 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time)
  • KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time)

Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations.

About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Inquiries Media: Kathleen Reid; media@abcellera.com, +1(604)724-1242 Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116

1 Year AbCellera Biologics Chart

1 Year AbCellera Biologics Chart

1 Month AbCellera Biologics Chart

1 Month AbCellera Biologics Chart

Your Recent History

Delayed Upgrade Clock